Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N5NM
|
|||
| Former ID |
DCL000911
|
|||
| Drug Name |
Org-23366
|
|||
| Synonyms |
SCHEMBL7887966; CHEMBL2078915
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Preclinical | [1] | |
| Company |
Akzo Nobel
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H30F2N2O
|
|||
| Canonical SMILES |
C1CCN(C1)C(=O)CCCN2CCC(=C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC2
|
|||
| InChI |
1S/C26H30F2N2O/c27-23-9-5-20(6-10-23)26(21-7-11-24(28)12-8-21)22-13-18-29(19-14-22)15-3-4-25(31)30-16-1-2-17-30/h5-12H,1-4,13-19H2
|
|||
| InChIKey |
FZWURHPZIJCZOY-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.